RxDoctor Payments Data

Virginia Laliberte, APRN

Nurse Practitioner · Hot Springs, ARNPI 1215414560

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $16,595 of the $20,806 with a category attached, or 79.8%. 60 manufacturers reported payments, led by AstraZeneca at 25.2% of the total. 2025 is the largest year on record at $5,865, 2.1 times the $2,753 reported in 2021. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,806in general payments, 2019–2025

Across 725 payments — averaging $28.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Novartis$2K
  • Beigene USA, Inc.$1K
  • GSK$761
  • Incyte Corporation$596
  • AbbVie$589
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$7804%
  • Speaking & faculty fees$3,00014%
  • Food & beverage$16,59580%
  • Education$4312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)54$5,252
Novartis117$1,648
Beigene USA, Inc.9$1,138
GSK36$761
Incyte Corporation19$596
AbbVie18$589
Merck31$539
Exelixis Inc.24$522
Gilead16$497
Bristol Myers Squibb45$470
Johnson & Johnson(2 entities)26$464
Bayer17$457
Amgen22$406
Astellas Pharma US Inc14$394
Takeda Pharmaceuticals U.S.A., Inc.13$391
Pfizer23$377
Eisai Inc.19$375
Daiichi Sankyo Inc.17$365
Karyopharm Therapeutics Inc.14$351
Myriad Genetic Laboratories, Inc.4$350
Lilly USA, LLC6$256
Pharmacosmos Therapeutics Inc.9$234
Sanofi11$234
Array Biopharma Inc11$211
Regeneron Healthcare Solutions, Inc.9$209
Seagen Inc.12$198
EMD Serono, Inc.4$187
Epizyme, Inc.5$152
AVEO Pharmaceuticals, Inc.4$151
CTI Biopharma Corp.2$141
Boston Scientific1$140
Morphosys, US Inc.7$136
Sobi, Inc8$130
Pharmacyclics LLC, An Abbvie Company5$130
Otsuka America Pharmaceutical, Inc.1$125
Alnylam Pharmaceuticals Inc.1$123
Progenics Pharmaceuticals, Inc.1$111
Biohaven Pharmaceutical Holding Company Ltd.1$108
Sirtex Medical Inc1$105
Janssen Scientific Affairs, LLC1$104
Grifols USA, LLC1$100
Boehringer Ingelheim5$100
Geron Corporation5$82
Rigel Pharmaceuticals, Inc.5$76
Sumitomo Pharma America, Inc.3$76
Servier Pharmaceuticals LLC4$73
E.r. Squibb & Sons, L.L.C.4$67
AMAG Pharmaceuticals, Inc.3$64
Celltrion USA Inc.3$61
Puma Biotechnology, Inc.4$58
Mirati Therapeutics, Inc.3$58
Stemline Therapeutics Inc.3$57
Spectrum Pharmaceuticals Inc.3$56
Ipsen Biopharmaceuticals, Inc3$53
Myovant Sciences Inc.3$52
Genentech USA, Inc.3$48
Genmab U.S., Inc.3$41
Pharmaessentia USA Corporation2$40
Tersera Therapeutics LLC2$38
Beone Medicines USA, Inc.2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,806 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$15,480
Medicare patients
73
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate13$224,772
Letrozole36$884
Tamoxifen Citrate19$486
Dexamethasone24$481
Ondansetron Hcl23$350
Cephalexin12$278
Hydroxyurea15$257
Prednisone33$183
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)12$88
Levothyroxine Sodium12$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$596$224,77213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →